Targeted Molecular Therapies in Allergy and Rhinology

Cecelia C. Damask*, Matthew W. Ryan, Thomas B. Casale, Mario Castro, Christine B. Franzese, Stella E. Lee, Joshua M. Levy, Sandra Y. Lin, Peter A. Lio, Anju T. Peters, Michael P. Platt, Andrew A. White

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Biologic agents, monoclonal antibodies that target highly-specific molecular pathways of inflammation, are becoming integrated into care pathways for multiple disorders that are relevant in otolaryngology and allergy. These conditions share common inflammatory mechanisms of so-called Type 2 inflammation with dysregulation of immunoglobulin E production and eosinophil and mast cell degranulation leading to tissue damage. Biologic agents are now available for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, eosinophilic granulomatosis with polyangiitis (EGPA), atopic dermatitis (AD), and chronic spontaneous urticaria (CSU). This paper summarizes the diagnosis and management of these conditions and critically reviews the clinical trial data that has led to regulatory approval of biologic agents for these conditions.

Original languageEnglish (US)
Pages (from-to)S1-S21
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume164
Issue number1_suppl
DOIs
StatePublished - Jan 2021

Keywords

  • T2 inflammation
  • allergic asthma
  • anti-IL-13
  • anti-IL-4
  • anti-IL-5
  • anti-IgE
  • anti-TSLP
  • aspirin-exacerbated respiratory disease
  • asthma
  • atopic dermatitis
  • benralizumab
  • biologic agent
  • biologics
  • chronic rhinosinusitis with nasal polyposis
  • chronic spontaneous urticaria
  • dupilumab
  • eosinophilia
  • eosinophilic asthma
  • eosinophilic granulomatosis with polyangiitis
  • mepolizumab
  • omalizumab
  • reslizumab
  • tezepelumab
  • unified airway

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Targeted Molecular Therapies in Allergy and Rhinology'. Together they form a unique fingerprint.

Cite this